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Aims: Myocardial infarction (MI) is the most common cause of heart failure. Excessive 55 
production of reactive oxygen species plays a key role in the pathogenesis of cardiac 56 
remodeling after MI. NADPH with Nox2 as the catalytic subunit is a major source of superoxide 57 
production and expression is significantly increased in the infarcted myocardium, especially by 58 
infiltrating macrophages. While microRNAs (miRNAs) are potent regulators of gene expression, 59 
and play an important role in heart disease, there still lacks efficient ways to identify miRNAs 60 
that target important pathological genes for treating MI. Thus, the overall objective was to 61 
establish a miRNA screening and delivery system for improving heart function after MI using 62 
Nox2 as a critical target. 63 
 64 
Methods and Results: By utilizing the miRNA-target screening system comprised of a self-65 
assembled cell microarray(SAMcell), three miRNAs, miR-106b, miR-148b, and miR-204, were 66 
identified that could regulate Nox2 expression and its downstream products both in human and 67 
mouse macrophages. Each of these miRNAs were encapsulated into polyketal (PK3) 68 
nanoparticles that could effectively deliver miRNAs into macrophages. Both in vitro and in vivo 69 
studies in mice confirmed the PK3-miRNAs particles could inhibit Nox2 expression and activity, 70 
and significantly improve infarct size and acute cardiac function after MI. 71 
 72 
Conclusions: Our results show that miR-106b, miR-148b and miR-204 were able to improve 73 
heart function after myocardial infarction in mice by targeting Nox2 and possibly altering 74 
inflammatory cytokine production. This screening system and delivery method could have 75 
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New and noteworthy: Nox2 is a promising target for treating cardiovascular disease but there 83 
are no specific inhibitors.  Finding endogenous signals that can target Nox2 and other 84 
inflammatory molecules is of great interest.  In this study, we used high-throughput screening to 85 


















Myocardial infarction (MI) is the leading cause of heart failure (HF), which results in tremendous 104 
morbidity and mortality worldwide (10). MI leads to scar formation and adverse cardiac 105 
remodeling including changes in the molecular and structural components of the myocardium, 106 
which lead to cardiac dysfunction (1). Following MI, circulating blood monocytes respond to 107 
chemotactic factors, migrate into the infarcted myocardium, and differentiate into macrophages. 108 
In addition, neutrophils and other inflammatory cells migrate to the injured myocardium acutely 109 
and initiate a wound healing response (7). While studies show that low levels of reactive oxygen 110 
species (ROS) are physiologically important, production of excessive amounts of ROS is a key 111 
event involved in post-MI pathogenesis (8). ROS modulate several processes during cardiac 112 
remodeling, including interstitial fibrosis, and cardiomyocyte apoptosis and hypertrophy (4, 23).  113 
Many studies demonstrate that a major source for ROS in the heart comes from a family of 114 
nicotinamide adenine dinucleotide phosphate- (NADPH) oxidase enzymes (5). NADPH oxidase 115 
is a multi-subunit enzyme consisting of membrane proteins (gp91phox otherwise known as Nox 116 
and p22phox) and several intracellular associated proteins (p47phox, p67phox, Rac).  Five Nox 117 
isoforms (Nox1 to Nox5) exist and are thought to the major indispensable subunit. Among these, 118 
Nox2 is expressed in cardiomyocytes, fibroblasts, and endothelial cells, and is thought to be 119 
dominant Nox isoform contributing to cardiac superoxide levels (O2-) production (2, 23). 120 
Evidence shows that both in animal models of MI and patients with end-stage heart failure, 121 
Nox2 expression is significantly increased in the infarcted myocardium, primarily in 122 
macrophages and myocytes (14, 19). Nox2 knockout mice show reduced cardiomyocyte 123 
apoptosis and adverse remodeling after MI and attenuate interstitial fibrosis following aortic 124 
constriction (12, 23). Recent studies show that Nox2 overexpression in cardiomyocytes does 125 
not alter infarct size, but rather long-term remodeling, indirectly demonstrating a role of 126 
inflammatory cell Nox2 in this process (27). In addition, as there is no specific inhibitor of Nox2, 127 
studies from our own laboratory have shown that Nox2 siRNA delivered in polymeric 128 
nanoparticles can attenuate acute cardiac dysfunction following MI as a potential therapeutic 129 
alternative (29). 130 
MicroRNAs (miRNAs) are endogenous small noncoding RNAs, about 22 nucleotides in 131 
length, which can mediate post-transcriptional gene silencing by binding to the 3’-untranslated 132 
regions (3’UTR) of target mRNAs and inducing translational inhibition or RNA decay(18). 133 
miRNAs are involved in diverse biological progresses, including cellular differentiation, 134 
proliferation, apoptosis, and migration (15, 30, 37). miRNAs have been demonstrated as a 135 
significant regulation factor in cardiovascular diseases. For example, miR-24 has been shown to 136 
be upregulated after cardiac ischemia and its inhibition can prevent endothelial cell apoptosis 137 
and increase vascularity, which results in preservation of cardiac function and survival (9). 138 
Meanwhile, overexpression of miR-21 significantly decreased infarct size in mice after 139 
ischemia/reperfusion (IR) injury (25). Another study reportedmiR-34a to be up regulated after MI 140 
(34). Knockdown of miR-34a in mice could significantly improve hearts post-MI remodeling. 141 
The critical challenge in miRNA therapy for cardiac disease includes identifying miRNAs 142 
that can target important genes and delivering them into specific cells efficiently. A certain 143 
miRNA normally has hundreds of targets, which is difficult to validate only by database 144 
prediction. Most published works using high-throughput miRNA target validation are used to 145 
identify targets of a miRNA (13, 24, 31). However, for a specific pathological disease, in which 146 
we already know which genes play important roles, it is more useful to find and select miRNAs 147 
that can target those genes directly. As Nox2 has no specific inhibitor and plays such an 148 
important role in post-MI pathogenesis, finding new ways to reduce expression could generate 149 
new therapeutic options.  Moreover, to date, there have been no reports of miRNAs that target 150 
Nox2 directly and reduce expression.  In this study, we demonstrate use of a self-assembled 151 
cell microarray (SAMcell) to find miRNAs that target Nox2 and deliver them into myocardial 152 
macrophages via acid-degradable polymers previously shown to deliver siRNA in to 153 
macrophages (29). The SAMcell system had been demonstrated for its efficient and accurate 154 
miRNA targeting identification by our previous work (35). SAMcell assays using the 3’UTR of 155 
Nox2 identified many potential miRNAs that were then tested in reporter cells, as well as mouse 156 
and human macrophages. Validated miRNA were loaded within polyketal nanoparticles for 157 





Cell culture procedures 163 
miRNA mimics were obtained from GenePharma and Sigma. 293T and Hela cells were cultured 164 
in high-glucose Dulbecco’s Modified Eagle Medium (DMEM) containing 10% fetal bovine serum 165 
(FBS), 100 units/ml penicillin and 0.1 mg/ml streptomycin (P/S). RAW 264.7 and THP-1 cells 166 
were cultured RPMI 1640 containing same amounts of FBS and P/S as above. All cells were 167 
cultured under humidified conditions in 5% CO2 at 37°C. When seeding, cells were washed with 168 
PBS and incubated in 0.25% trypsin containing 5mmol/L EDTA. After centrifugation, cells were 169 
diluted in media, counted via hemocytometer, and then seeded at the appropriate concentration. 170 
To achieve transient expression, plasmids and miRNA mimics were transfected using 171 
Oligofectamine (Invitrogen). The cell number and nucleotide were determined per 172 
manufacturer’s protocol. To establish stable cell lines, the indicated lentiviral vectors were 173 
packaged and transfected into cells. In brief, lentivirus was packaged into 293T cells, and then 174 
harvested and infected to Hela cells. After 72 hours, cells were selected and collected by FACS. 175 
 176 
Luciferase assays 177 
For luciferase assays, the 3’UTR of human or mouse Nox2 were cloned into pGL3 plasmids 3’ 178 
to the firefly luciferase gene. Four x 104 293T cells were co-transfected with 200 ng of the 179 
indicated pGL3 firefly luciferase construct and 20 ng of a pGL3 Renilla luciferase used as a 180 
normalization control. At the same time, the indicated miRNA expression plasmid or mimics 181 
were transfected. After 48 hours, cells were lysed and luciferase activities were measured using 182 
the Dual Luciferase Reporter Assay System (Promega). 183 
 184 
Screening of miRNA-targets using self-assembled cell microarray (SAMcell) 185 
The fabrication of the SAMCell microarray had been previously described (36). In brief, the 186 
glass slides (22 mm x 22 mm) were covered with Poly (N-isopropylacrylamide) (Aldrich) 187 
dissolved in ethanol (6% w/v). The slides were etched via a shadow mask by oxygen plasma for 188 
3.5 min at 200w power. The reverse transfection protocol described below refers to a previous 189 
description (36). The miRNA mimic library mixed in the reverse transfection reagent was printed 190 
on the chip (Suzhou Genoarray Co., Ltd.) Next, the slides were fixed in a 6-well plate by melted 191 
wax. A reporter system was built that expresses an enhanced green fluorescent protein (eGFP). 192 
Then the 3’UTR of human Nox2 was cloned as the 3’UTR of eGFP and a stable Hela cell line 193 
expressing the reporter system was selected by FACS as described above. Over 260 miRNAs 194 
were printed on the SAMcell chip. Then, 5 x 105 cells containing 3’UTR reporter were 195 
transferred into each well. After culturing for 48 hours, the dishes were moved to room 196 
temperature for 5 min and washed with PBS for three times to remove the polymer. Average 197 
fluorescent intensity of each cell island were collected and analyzed. The cut-off value was 198 
obtained on the basis of the Kolmogorov-Smirnov Z-test in 50 control experiments. Six 199 
replicates were repeated for each miRNA. 200 
 201 
Polyketal (PK3) synthesis 202 
PK3 was synthesized as described in our prior study (20). Briefly, the diols, 203 
cyclohexanedimethanol and 1,5-pentanediol were dissolved in distilled benzene and heated to 204 
100°C. Recrystallized p-toluenesulfonic acid (PTSA) was dissolved (~1 mg) in ethyl acetate and 205 
added to the benzene solution to catalyze the reaction. The polymerization reaction was 206 
initiated by the addition of equimolar 2,2-diethoxypropane (DEP). Additional 2,2-dimethoxy 207 
propane (DMP) and benzene were subsequently added to the reaction to compensate for loss 208 
of volume in the form of ethanol/methanol and the solvent benzene that had distilled off. After 209 
48h, the reaction was stopped with triethylamine and isolated by precipitation in cold hexanes. 210 
The solid polymer was filtered off, rinsed in hexanes and vacuum dried prior to storage at -20°C. 211 
Polymer molecular weight/polydispersity was confirmed by gel permeation chromatography. 212 
 213 
Preparation of miRNA-loaded PK3 particles 214 
PK3-miRNA particles were prepared following the protocol for PK3-siRNA particles(29). 215 
Briefly,1mg miRNA in water and 2.2 mg of cationic lipid N-[1-(2,3-Dioleoyloxy)propyl]-216 
N,N,Ntrimethylammonium methysulfate (DOTAP) dissolved in dichloromethane (DCM) were 217 
brought to one phase by addition of 1.05 mL of methanol. After 15 min incubation, an additional 218 
0.5 mL of water and DCM were added and the mixture was vortexed, and centrifuged at 750 219 
rpm for 5 min. The miRNA:DOTAP complex in the bottom organic layer was encapsulated in 220 
PK3 via an oil/water single emulsion procedure, using DCM as the oil phase and polyvinyl 221 
alcohol (PVA) as the surfactant stabilizer. 1 mL of DCM containing ion-paired miRNA was added 222 
to 40 mg of PK3 with 1 mg of chloroquine free base. This solution was homogenized into 8 mL 223 
of 5% (w/v) PVA solution at the highest setting in the Power Gen 500 (Fisher Scientific) for 30 224 
seconds, and sonicated at an intermediate speed (Sonic dismembrator model 100, Fisher 225 
Scientific) with 10 pulses of 1 sec duration. The emulsion was then dispersed in a 20 mL of 226 
0.5% PVA solution and stirred for a period of 4-5 h to allow the DCM to evaporate. The resulting 227 
particles were isolated by centrifugation (15000 rpm, 20 min), washed three times, freeze-dried 228 
and stored at -20°C for further use. 229 
 230 
In vitro delivery of PK3-miRNA particles 231 
For in vitro studies, RAW 264.7 macrophages or PMA induced THP-1 cells were plated in 6-well 232 
plates at a density of 1 x 106cells per well. After 24 h, cells were treated with indicated PK3-233 
miRNA particles at a concentration of particles equivalent to 2 µg miRNA/well. For gene 234 
expression studies, following 48 hours of treatment, the cells were harvested and RNA or 235 
protein extracted. For assessment of functional activity of Nox2-NADPH, the cells were kept in 236 
wells for analysis of O2- production. 237 
 238 
Gene expression by real-time PCR and western blot 239 
Total RNA from cells was isolated using Trizol (Invitrogen) according to the manufacturer’s 240 
protocol. Complementary DNA (cDNA) was synthesized using SuperScript III kit (Invitrogen). 241 
Real time PCR was performed using Power SYBR Green (Invitrogen) master mix with Applied 242 
Biosystems StepOne Plus real time PCR system. The primers used are listed in Supplementary 243 
Table 1.  Nox2 gene expression levels were normalized to the housekeeping gene GAPDH. 244 
Total protein extracted from cells were resolved by SDS-PAGE and then transferred to a 245 
polyvinylidene difluoride membrane (Millipore Corporation). The membranes were probed with 246 
antibodies against Nox2 (Abcam) and GAPDH (Abcam). The images were obtained and 247 
quantified by Image J software. 248 
 249 
Supernatant Collection and Enzyme-Linked Immunosorbent Assay 250 
Forty-eight hours after transfection with indicated miRNAs, Raw246.7 media were collected for 251 
analysis. The concentrations of IL-1β, IL-6, and TNF-α in the supernatant were determined by 252 
enzyme-linked immunosorbent assay (R&D Systems). All assays were performed according to 253 
the manufacturer’s protocol. 254 
 255 
Detection of superoxide in vitro and in vivo 256 
To test Nox2 activity in vitro, production of O2- after stimulation with phorbol-12-myristate 13-257 
acetate (PMA) was measured by staining with fluorescent ROSstar 650 dye. Forty-eight hours 258 
after transfection with miRNAs or treatment with PK3-miRNA particles, media was aspirated 259 
from wells containing induced THP-1 or RAW 264.7 macrophages and then washed with fresh 260 
cold Krebs-Hepes buffer (KHB). Then 10 µM PMA was added to each well and incubated for 10 261 
min at 37°C. After this, 25 µM dye was added to wells and incubated for 20 minutes under dark 262 
conditions. For in vivo studies, frozen sections were washed by KHB and stained with 263 
dihydroethidium (DHE) directly for 20 minutes. Fluorescent images were taken by Nikon 264 
fluorescent microscope using equal exposure times for all samples. 265 
 266 
Myocardial infarction and particle injection 267 
Studies were conducted under a randomized and blinded manner. Adult male C57BL/6 mice (>8 268 
weeks) were used and assigned to five groups. One group was subjected to sham surgery, 269 
while the other four groups received permanent myocardial infarction. The surgeries were 270 
conducted as described previously (26). Briefly, the animals were anesthetized by isoflurane (1-271 
3% inhaled). Following tracheal intubation, the heart was exposed by separation of the ribs. 272 
Myocardial infarction was achieved by ligation of the left anterior descending coronary artery. 273 
For mice getting particle injections, 50 µL of indicated particle was injected into the cyanotic 274 
ischemic zone through a 30-gauge needle immediately after ligation. The dose of miRNA 275 
injected was 5 µg/kg. After injection, the chests were closed and animals were recovered on a 276 
heating pad. Animals were euthanized by regulated carbon dioxide inhalation in a closed 277 
chamber per proper guidelines. Functional assessments were made at 3 days following 278 
surgeries using echocardiography. These studies conformed to the Guide for the Care and Use 279 
of Laboratory Animals published by the US National Institutes of Health and all animals studies 280 
were approved by Emory University Institutional Animal Care and Use Committee. 281 
 282 
Immunohistochemistry 283 
Fresh heart tissue was frozen in Tissue-Tek OCT and 5µm sections were made. After washing 284 
with PBS, sections were fixed by 4% formaldehyde solution an then incubated with goat serum 285 
for 1 h. Nox2 antibody diluted in goat serum was added to the sections and incubated at 4°C 286 
overnight. After that, sections were washed 3 times using PBS-Tween and incubated with 287 
fluorescent secondary antibody for 2 h at room temperature. At least 3 sections from each 288 
animal were analyzed. Nuclei were stained by Hoechst dye. Images were taken by Nikon at 289 
identical exposures and analyzed by ImageJ software. 290 
 291 
Echocardiography and infarct size 292 
Anesthetized mice were subjected to echocardiography 3 days after MI surgery. Short axis 293 
values of left ventricular diameter were obtained using a Vevo 770 small animal ultrasound 294 
system (Visualsonics). An average of 3 consecutive cardiac cycles was used for each 295 
measurement and performed three times in an investigator-blinded manner. Fractional 296 
shortening (FS) was calculated as (end-diastolic diameter - end-systolic diameter)/end-diastolic 297 
diameter and expressed as a percentage. 298 
 Myocardial infarct size was evaluated using 2,3,5-triphenyltetrazolium chloride (TTC) 299 
staining and Evans Blue dye in which the percent area of infarction was calculated as the 300 
infarcted area (TTC stained) divided by the ischemic area at risk at 24 hours following injury. 301 
 302 
Statistics 303 
For statistical analysis, two-sided Student t tests were used for in vitro studies, while one-way 304 
ANOVA tests were used for in vivo studies. A p-value < 0.05 was considered statistically 305 
significant. * P < 0.05; ** P < 0.01; *** P < 0.001. Error bars indicate SD of at least three 306 




SAMCell screening to target human Nox2 311 
The schematic diagram of screening system is shown as Figure 1. The 3’UTR of human Nox2 312 
was cloned into reporter system and266 miRNAs, conserved between human and mouse, were 313 
screened by SAMCell assay. The top effective miRNAs are listed in Table 1. Three miRNAs, 314 
miR-106, miR-148b, and miR-204 were selected for further study after literature research and 315 
miRNA target prediction. Each of them have one or more predicted binding sites in human Nox2 316 
3’UTR according to Targetscan database, shown in Table 2. 317 
 318 
Selected miRNAs functional validation 319 
To validate each miRNA’s ability to suppress human Nox2, we performed luciferase assaysin 320 
293T cells cloned with the 3’UTR of Nox2 downstream of luciferase. As shown in Figure 2A, all 321 
of the three miRNAs significantly decreased luciferase expression compared to control (miR-322 
106b=78.5+8.6%, P<0.01; miR-148b=78.6+11.1%, P<0.01; miR-204=56.2+8.4%, 323 
P<0.001).Additionally, we mutated the predicted binding sites in the 3’-UTR and found no effect 324 
of the selected miRNAs.  To determine whether their regulation was conserved, we also 325 
validated the selected miRNAs using mouse Nox2 3’UTR downstream of luciferase. Similar to 326 
human Nox2, luciferase containing mouse Nox2 3’UTR was also significantly decreased by 327 
these miRNAs compared to control group (miR-106b=66,6+6.8%, P<0.001; miR-328 
148b=70.1+8.2%, P<0.001; miR-204=46.7+2.7%, P<0.001, Figure 2B).  329 
 We also transfected these miRNAs mimics to induced human macrophages (THP-1 330 
cells) and a mouse macrophage cell line (RAW 264.7). Nox2 mRNA and protein levels were 331 
detected by real-time PCR and western blot, respectively. As expected, compared to a 332 
scrambled control miRNA group, all 3 miRNAs decreased both human and mouse Nox2 333 
expression at the gene and protein level by about 40% (Figure 2C and 2D). 334 
 335 
In vitro functional knockdown of Nox2 downstream production 336 
To determine whether Nox2 knockdown by miRNAs resulted in functional changes, we 337 
transfected THP-1 induced and RAW 264.7 macrophages with miRNAs separately and 48 hours 338 
later, they were stimulated with PMA to induce O2- production. ROSstar 650 dye, a fluorescent 339 
probe for intracellular ROS, was then added to the cells. Fluorescence intensity was expressed 340 
as fold change in O2- production normalized to basal O2- levels. As shown in Figure 3A, after 341 
stimulation with PMA, O2- production was increased, while each miRNA treatment groupshowed 342 
significantly decreased levels in O2- production compared to the control group in THP-1 induced 343 
(upper) and RAW 264.7 (bottom) macrophages. Quantification results were shown as Figure 344 
3B for THP-1 induced macrophages and Figure 3C for RAW 264.7 macrophages. In order to 345 
investigate if the inhibition of O2- production was a result of decreased Nox2, we overexpressed 346 
Nox2 protein concurrently with miRNAs transfection. As shown in Figure 3D-E, O2- production 347 
level was partially rescued when Nox2 was overexpressed. 348 
 We also examined whether the miRNA identified were additive, and whether there were 349 
effects on other inflammatory targets.  There was no significant additive effect by delivery of all 350 
three miRNAs together compared to the single miRNA alone both for Nox2 expression level and 351 
O2- production level (Figure 4A and 4B). We also investigated expression of IL-1α, IL-6 and 352 
TNF-α by real-time PCR in RAW 264.7 macrophages after transfection with miRNAs. As Figure 353 
4C-E show, these miRNAs significantly decreased the mRNA expression level of these pro-354 
inflammatory genes as well, except miR-148b on TNF-α. To further identify miRNAs’ effects on 355 
the protein level of these three genes, enzyme-linked immunosorbent assay was used and the 356 
expression of secreted proteins were all inhibited when any miRNA was overexpressed, as 357 
shown in Figure 4F-H. 358 
 359 
Nanoparticle uptake by macrophages 360 
After validation of individual miRNA function on Nox2 expression and downstream O2-361 
production, we sought to validate our previously used in vivo delivery system with miRNA in 362 
cultured cells.  miRNAs encapsulated within PK3 polymer(PK-miRNA)showed similar loading 363 
levels as our prior publications (1 µg per mg particle).  Cells were incubated with the indicated 364 
PK-miRNA formulation and expression of the delivered miRNA was evaluated with real-time 365 
PCR.  As shown in in Figure 5A, each formulation was able to increase expression of their 366 
respective cargo at least 500-fold, indicating effective delivery.   367 
 We treated RAW 264.7 macrophages with PK-miRNA particles for 48 hours and Nox2 368 
mRNA expression level was determined by real-time PCR. As shown in Figure 5B, treatment 369 
with any of the particle formulations significantly reduced Nox2 gene expression (miR-370 
106b=58.9+5.7%, P<0.001; miR-148b=63.7+7.9%, P<0.001; miR-204=51.1+12.8%, P<0.001). 371 
O2- production was also measured and, similarly to gene expression, treatment with any PK-372 
miRNA particle significantly decreased production as compared to the control group (PK3-NC, 373 
Figure 5C and 5D).  374 
 375 
PK-miRNAs delivery in vivo 376 
To determine the in vivo efficiency of miRNA mediated-Nox2 suppression, adult male C57BL/6 377 
mice were randomized into 5 treatment groups. Control mice were subjected to sham surgery, 378 
while the other four groups received MI surgery followed by injection of PK-miRNA or a negative 379 
control scrambled miRNA particle (PK-NC). At 3-days post injury, hearts were harvested and 380 
expression of Nox2 was determined by immunofluorescence staining of frozen sections. As 381 
shown in Figure 6A and 6B, there was a significant increase in Nox2 staining with PK-NC 382 
treatment following MI as compared to sham mice (about 3-fold, P<0.001). Compared to PK-NC 383 
group, each PK-miRNA treatment group demonstrated significantly reduced staining of 384 
Nox2(miR-106b=43.2+6.8%, P<0.001; miR-148b=24.8+6.3%, P<0.001; miR-204=35.9+5.1%, 385 
P<0.001). Additionally, O2-levels were determined by DHE staining on frozen sections. Similar to 386 
Nox2 expression levels, each PK-miRNA treatment significantly reduced the elevated DHE 387 
staining at least 50% (Figure 6C and 6D).To further identify if Nox2 was specifically inhibited in 388 
macrophages, we stained sections for Nox2 and CD68. As shown in Figure 6E, there was 389 
decreased co-staining in PK-miRNA treatment group, compared to PK-NC group. 390 
 To determine the effect of PK-miRNAs delivery on acute cardiac function after MI, 391 
echocardiography data was collected 3 days after injury. As shown in Figure 7A, 7B and 7C, MI 392 
significantly reduced cardiac function as measured in absolute change in fractional shortening 393 
and ejection fraction 3 days post-injury. Treatment with each PK-miRNA particle significantly 394 
improved function, restoring it to sham levels. To further examine functional changes, we also 395 
measured infarct size at 24 hours by TTC staining.  As the representative images and grouped 396 




Substantial evidence shows that oxidative stress due to excessive ROS such as O2- plays an 401 
important role in the development of post-MI cardiac dysfunction (8, 23). Antioxidant treatment 402 
following MI in animal models improves cardiomyocyte survival, attenuates ventricular 403 
remodeling, and results in preservation of left ventricular function (4). NAPDH oxidases are 404 
major sources of O2- in the heart andthe family of gp91 proteins (Nox 1-5) is an important 405 
catalytic unit of the NADPH oxidase (23). Nox2 is mainly expressed in macrophages, 406 
fibroblasts, endothelial cells and cardiomyocytes (2) and is significantly increased in the 407 
myocardium following MI with the massive influx of inflammatory cells (14, 19). Nox2 is also 408 
increased in human cardiomyocytes following MI (14). Nox2 knockout mice are protected from 409 
post-MI dysfunction (12, 23), and studies from our own laboratory show that siRNA against 410 
Nox2 encapsulated in nanoparticles can protect against acute MI dysfunction (29). Therefore 411 
finding additional way to target Nox2 could be a promising therapeutic approach for preserving 412 
function following acute MI. 413 
 414 
In the current report, we successfully identified several miRNAs targeting Nox2 with the use of a 415 
high-throughput miRNA-target screening system and validated their targeting using a luciferase 416 
reporter system with the 3’UTR of Nox2.  We also confirmed their function by testing Nox2 417 
expression and function in both human and mouse macrophage cell lines. To date, there had 418 
been no studies that identified a miRNA that directly bound the Nox2 3’UTR and decreased 419 
expression. The SAMcell assay provided a straightforward way to identify miRNAs that target a 420 
specific gene. In our previous studies, the performance of this system had been demonstrated 421 
using a phenotypic approach to determine miRNAs that regulated processes involved in cancer 422 
(35). In this study, miRNAs were selected that were conserved between human and mouse in 423 
order to test potential human targets in mouse models of MI. Three specific miRNAs were 424 
chosen for more detailed analysis due to prior publications underscoring their involvement in 425 
post-MI healing. Following MI, miR-106b reduced apoptosis via inhibition of p21 expression 426 
(22), and has also been shown to target the pro-inflammatory cytokine IL-8 (6). The second hit, 427 
miR-148b, has been reported to negatively regulate LPS-induced cytokine production in 428 
dendritic cells, including IL-6, IL-12, and TNF-α, and plays an important role in immune 429 
regulation (21). In addition, a significantly decreased expression of miR-148b was observed in 430 
isoproterenol-induced myocardial injury and fibrosis; expression was increased when apocynin 431 
treatment was used to reverse this (33). Finally, our third hit, miR-204, was decreased after 432 
ischemia-reperfusion (IR) injury in mice and overexpression of miR-204 protected the 433 
cardiomyocytes against IR-induced autophagy (32).  434 
 435 
After selection of these three miRNAs, their inhibition of both human and mouse Nox2 was 436 
validated by several methods. Luciferase assays using the Nox2 3’UTR demonstrated they 437 
could each decrease Nox2 expression directly by canonical miRNA regulation. Real-time PCR 438 
and western blot studies confirmed that all three miRNAs decreased Nox2 levels at the gene 439 
and protein levels (Figure 2C-F).DHE staining for PMA-induced superoxide levels (a surrogate 440 
of Nox2 activity) also showed the functional benefit of the miRNA-induced decrease in Nox2 441 
levels. 442 
 443 
Once miRNAs were selected and validated, we sought to utilize an efficient delivery system for 444 
targeting macrophages in vivo. Polyketals are a class of delivery vehicles formulated from a 445 
class of polymers that contain pH-sensitive, hydrolyzable ketal linkages in their backbone. We 446 
had used the polyketal PK3 to deliver miRNA to bone marrow mononuclear cells to induce 447 
pluripotency (28). There was no difference in miRNA transfection efficiency between commercial 448 
transfection reagent (Oligofactamine) and PK3 nanoparticles (data not shown). Additional 449 
published studies from our laboratory demonstrated that PK3 nanoparticles were retained in the 450 
myocardium after injection and could be used to deliver siRNA following MI in mice (29). When 451 
engaged by macrophages, particles were taken up into phagosome/endosomes where they 452 
degrade due to the acidic environment, leading to release of cargo into the cytoplasm of 453 
macrophages (over 80% transfection efficiency). In that study we successfully delivered Nox2 454 
siRNA into cardiac macrophages by PK3 particles and observed a significant improvement in 455 
heart function after MI. 456 
 457 
Despite our prior study showing beneficial effects of delivery of siRNA to Nox2, delivery of 458 
miRNA might have potential advantages. Firstly, miRNA is more natural as there is no siRNA in 459 
mammalian cells. miRNA is viewed as endogenous and purposefully expressed products in an 460 
organism’s own genome, whereas siRNA is thought to be primarily exogenous in origin, derived 461 
directly from viruses, transposons, or transgene triggers (3). Additionally, introduction of too 462 
much siRNA could result in nonspecific events due to activation of innate immune response 463 
(17). Secondly, miRNA could target many genes and sometimes from the same pathways. For 464 
example, let-7, which was shown to be able to directly regulate some key cell cycle proto-465 
oncogenes, e.g., RAS, CDC25a, CDK6, and cyclin D at the same time, was a key regulator of 466 
cell proliferation (16). Likewise, miR-23b plays an important role in tumor metastasis since it 467 
regulates a cohort of pro-metastatic targets, including FZD7, MAP3K1, TGFBR2 and PAK2 (36). 468 
To validate this hypothesis in this study, we examined expression levels of other pro-469 
inflammatory genes such as IL-1α, IL-6 and TNF-α by real-time PCR and ELISA assay in RAW 470 
264.7 cytokines after transfection with miRNAs and found that all miRNAs also targeted other 471 
inflammatory genes, though it is unclear as to whether this was indirect or direct. 472 
 473 
We next examined the efficacy of these particles in vivo, in a mouse model of MI.  Similar to our 474 
prior studies, we delivered particles immediately following ligation to the border zone of the 475 
infarct. In keeping with published studies (12, 14, 19), both Nox2 levels and superoxide levels 476 
were significantly increased following MI.  While Nox2 levels have been shown to be 477 
upregulated in cardiomyocytes, staining indicated upregulation in both cardiomyocyte and non-478 
cardiomyocyte origin, likely infiltrating inflammatory cells.  Double staining indicated that CD68-479 
positive macrophages had expression of Nox2 that was not present in any PK-miRNA treated 480 
groups.  While we did not identify the source of the superoxide, it was also likely inflammatory 481 
cells based on prior studies (4, 23). While it is possible that Nox2 was increased in myocytes, 482 
our published studies show that polyketals are not efficiently taken up by cardiomyocytes 483 
without surface modification of the nanoparticles (11, 20). Thus, any reduction in Nox2 in 484 
cardiomyocytes was likely indirect, possibly an effect of reduced local superoxide and 485 
inflammation. It would be interesting to encapsulate the miRNAs in modified particles and 486 
determine whether miRNA-mediated knockdown of Nox2 in cardiomyocytes is sufficient for 487 
protection, though this would be unlikely due to the large influx of inflammatory cells. 488 
Additionally, we did not measure other ROS such as hydrogen peroxide (H2O2), which could 489 
also mediate damage.  The role of H2O2 in acute MI is controversial and it remains a debate as 490 
to whether this is a valid target as H2O2 is also involved in important physiological processes.  It 491 
is also likely that reduced levels of O2- also resulted in decreases in H2O2 and understanding 492 
this balance could be an interesting topic for future consideration. After treatment with any PK3-493 
miRNA, Nox2 expression and O2-levelswere reduced significantly compared to the empty 494 
particle group. More importantly, an improvement in cardiac function and reduction in infarct size 495 
were observed in each PK3-miRNA formulation treatment group. These results corroborated 496 
reports that knockdown of Nox2 improves cardiac function after MI. 497 
 498 
In conclusion, we have found novel miRNA regulation of Nox2 expression by utilizing a high 499 
throughput miRNA-target screening method, the SAMcell assay, to narrow down potential 500 
targets, specifically miR-106b, 148b, and 204.  We validated the results in transfected cells, as 501 
well as human and mouse macrophages.  Combined with our efficient macrophage-specific 502 
delivery approach, these miRNAs were able to reduce Nox2 expression and activity in vivo, 503 
resulting in improved acute function.  With the robust nature of these systems, other 504 
inflammatory molecules can be studied to determine optimal miRNA candidates to modulate 505 
inflammation in vivo. 506 
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Table 1. 664 
 665 
Top listed results of SAMcell 666 
miRNA Fold Change P-value 
miR-106b 0.90005 0.000251 
miR-148b 0.901037 7.55E-05 
miR-21 0.905 0.019 
miR-135b 0.915 0.00039 
miR-296-5p 0.916 0.00053 
miR-590-5p 0.921 0.1019 
miR-33a 0.923 0.029 
Let-7f-1-3p 0.925 0.0498 
miR-29c* 0.926 0.004 
Let-7i 0.927 0.027 
miR-204 0.9278 0.008 
miR-221 0.931 0.121 
miR-190 0.934 0.117 
miR-7 0.935 0.058 




















Table 2. 686 
 687 
miRNAs-Nox2 predicting binding sites from Targetscan database 688 
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Figure 1.Schematic diagram of the screening strategy to identify miRNAs targeting 704 
human Nox2. miRNA mimics were printed on the self-assembled cell microarray together with 705 
the transfection reagent. Hela cells stably expressing enhanced green fluorescent protein 706 
(eGFP) fused with the 3’UTR from human Nox2 were seeded on the array. Human Nox2 siRNA 707 
was used as positive control (PC) and scrambled miRNA was used as negative control (NC). In 708 
total, 266 miRNAs with conserved sequences between humans and mice were screened. After 709 
bioinformatics analysis and validation, three miRNAs were chosen for further study. 710 
 711 
Figure 2.miRNAs regulated both humans and mice Nox2 expression. A and B, Relative 712 
luciferase activity in Hela cells transfected with indicated miRNAs or control vector with human 713 
(A) and mouse (B) Nox2 3’UTR driven reporter constructs, n=5.  Shaded bars in A show 3’;UTR 714 
with mutated predicted binding sites (Targetscan). C and D, Real-time PCR for Nox2 in PMA 715 
induced THP-1 (C) and RAW 264.7 (D) cells 48 hours after transfection with indicated miRNA or 716 
control vector. GAPDH was used as the loading control, n=3. E and F, Immunoblots for Nox2 in 717 
PMA induced THP-1 (E) and RAW 264.7 (F) cells 48 hours after transfected with indicated 718 
miRNAs or control vector. GAPDH was used as the loading control. **p<0.01, ***p<0.001 (t-719 
test). 720 
 721 
Figure 3.miRNAs inhibited superoxide production in humans and mice macrophages. A, 722 
Superoxide production levels in THP-1 (upper) and RAW 264.7 (bottom) cells were detected 723 
with ROSstar dye staining after stimulated by PMA and transfected with indicated miRNAs or 724 
control vector, n=3. Scar bar = 100 μm. B and C, Quantification of superoxide production levels 725 
in THP-1 (B) and RAW 264.7 (C) cells by comparing fluorescence intensity of indicated group. 726 
D and E, Representativeimages (D) and quantification (E) of superoxide production levels in 727 
RAW 264.7 when Nox2 was over expressed together with miRNAs transfection, 728 
n=3.*p<0.05,***p<0.001 (t-test). 729 
 730 
Figure 4. Comparison of miRNAs mix and single miRNA function and inhibition on pro-731 
inflammatory related genes. A, Real-time PCR for Nox2 mRNA in RAW 264.7 after 732 
transfection with indicated miRNA or a mixture of all 3 miRNAs normalized to miR-106b 733 
treatment.  Data show no difference between individual miRNAs or combinations, n=3. B, 734 
Quantification of relative fluorescence intensity with DHE staining in RAW 264.7 after 735 
transfection with indicated miRNA, result of miR-106b used as control. No significant difference 736 
among four groups, n=3.C-E, Real-time PCR for IL-1β (D), IL-6 (E), and TNF-α (F) mRNA in 737 
RAW 264.7 after transfection with indicated miRNA. F-H, ELISA assay for IL-1β (F), IL-6 (G), 738 
and TNF-α (H) protein level in RAW 264.7, n=3.*p<0.05, **p<0.01, ***p<0.001 (t-test). 739 
 740 
Figure 5.PK3-miRNAs nanoparticles redued Nox2 expression and activity in RAW 264.7 741 
cells. A, Fold change of miRNAs levels in RAW 264.7 cells after treated with indicated PK3-742 
miRNAs nanoparticles by real-time PCR. U6 was used as the loading control, n=3. B, Real-time 743 
PCR of Nox2 in RAW 264.7 cells after treatment with indicated PK3-miRNA or control 744 
nanoparticles. GAPDH was used as the loading control, n=3. C and D, Representative images 745 
(C) and quantification (D) of superoxide production levels in RAW 264.7 cells treated with 746 
indicated nanoparticles by ROSstar dye, n=3. ***p<0.001 (t-test). 747 
 748 
 749 
Figure 6.PK3-miRNAs nanoparticles inhibited Nox2 expression and activity in vivo.A and 750 
B, Representative images (A) and quantification (B) of Nox2 (red) levels by in situ 751 
immunostaining on frozen sections from indicated mouse heart tissues. Cell nuclei were stained 752 
by Hoechst (blue), n=5.Scar bar = 100 μm. C and D, Representative images (C) and 753 
quantification (D) of superoxide production levels by DHE staining on frozen sections from 754 
indicated mouse heart tissues. Cell nuclei were stained by Hoechst, n=5. Scar bar = 100 μm. 755 
**p<0.01; ***p<0.001 (One-way ANOVA followed by Bonferroni post-test). E, Representative 756 
images of Nox2 (red), CD68 (green) and cell nuclei (blue) by in situ immunostaining on frozen 757 
sections. 758 
 759 
Figure 7. PK3-miRNA nanoparticles improved cardiac function after MI. A, 760 
Echocardiographic pictures of mice 3 days after indicated treatment.  B and C, 761 
Echocardiographic parameters fractional shortening (B) and ejection fraction (C) from indicated 762 
group of mice,n=5. **p<0.01; ***p<0.001 (One-way ANOVA followed by Bonferroni post-test).D 763 
and E, Representative images (D) and grouped data (E) from infarct size experiments, n>4.  764 
**p<0.01, ***p<0.001 (One-way ANOVA followed by Bonferroni post-test). 765 
 766 







